Compare BioNano Genomics Inc (BNGO) vs KB Financial Group, Inc. (KB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs KB Financial Group, Inc. — how do they compare? BioNano Genomics Inc trades at $1.19 (market cap $13.66M), while KB Financial Group, Inc. trades at $117.63 (market cap $41.21B). The key difference: KB Financial Group, Inc. is far larger — about 3016.8× BioNano Genomics Inc's market cap, and KB Financial Group, Inc. pays a 2.67% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | KB | |
|---|---|---|
Market Cap | $13.66M | $41.21B |
Sector | Health | Financials |
52-Week High | $4.92 | $124.01 |
52-Week Low | $1.06 | $77.50 |
Enterprise Value | $16.26M | — |
Dividend Yield | — | 2.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
KB Financial trades at $117.63, down 2.57% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and rising revenue ($21.23T in 2025). Valuation metrics appear attractive with a P/E of 10.36 and P/B below 1. Recent news highlights momentum and dividend potential, while cash flow trends show volatility with a net inflow of $4.41T in 2025.
The outlook remains positive given earnings momentum and diversification into non-banking segments (43% of earnings). Risks include volatile cash flows and macroeconomic sensitivity. Analysts are mixed (33% Buy, 67% Hold), suggesting cautious optimism. The stock's current price near support at $117 offers a potential entry, but investors should monitor execution on non-banking targets and interest rate impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About KB Financial Group, Inc.
KB Financial is the parent company of KB Kookmin Bank, Korea's largest commercial bank, with a 13.1% share of loans as of 2021. Its predecessor banks were established in the 1960s as government policy banks and privatized in the 1990s. Its credit card subsidiary KB Kookmin Card is the number-three player behind Shinhan Card and Samsung Card. KB has in recent years expanded its nonbank business by buying LIG Insurance and Hyundai Securities, making KB a top-five player in nonlife insurance and in securities, and most recently by buying Prudential Life Insurance Korea. It also has KB Capital, which provides leasing and installment finance.
Read more on KB →
